{
    "id": "correct_subsidiary_00053_1",
    "rank": 25,
    "data": {
        "url": "https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/01c046450c311abad3e7ba36ca04de5f",
        "read_more_link": "",
        "language": "en",
        "title": "Drug pipelines, Patents, Clinical trials",
        "top_image": "https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/static/synapse-logo-us.png",
        "meta_img": "https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/static/synapse-logo-us.png",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "GE Healthcare AS",
            "Flutemetamol F-18",
            "Regadenoson",
            "Perflubutane"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Explore GE Healthcare AS with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 161 news, and 23 literature, Disease Domain:Nervous System Diseases, Technology Platform:Small molecule drug, Contrast agent, Diagnostic radiopharmaceuticals, Drug:Perflutren protein-type A microspheres(GE healthcare), Regadenoson, Flutemetamol F-18, Perflubutane, Mangafodipir Trisodium.",
        "meta_lang": "en",
        "meta_favicon": "/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/01c046450c311abad3e7ba36ca04de5f",
        "text": ""
    }
}